Role of mitochondrial DNA copy number alteration in human renal cell carcinoma

International Journal of Molecular Sciences

Volumn 17, Issue 6, 2016, Pages

  Lin, Chen Sung ^a,b,c   Lee, Hui Ting ^a,d,e   Lee, Ming Huei ^c   Pan, Siao Cian ^a,e   Ke, Chen Yeh ^a   Chiu, Allen Wen Hsiang ^a,f   Wei, Yau Huei ^a,d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b Taipei Hospital   (Taiwan)

^c FENG YUAN HOSPITAL   (Taiwan)

^d MACKAY MEDICAL COLLEGE   (Taiwan)

^e MACKAY MEMORIAL HOSPITAL   (Taiwan)

^f TAIPEI CITY HOSPITAL   (Taiwan)

Author keywords

Invasiveness; Mitochondrial biogenesis; Mitochondrial DNA copy number; Renal cell carcinoma; Warburg effect

Indexed keywords

6 PHOSPHOFRUCTOKINASE; CYCLOOXYGENASE 2; DOXORUBICIN; GLUCOSE 6 PHOSPHATE ISOMERASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; LACTATE DEHYDROGENASE; MITOCHONDRIAL DNA; MITOCHONDRIAL TRANSCRIPTION FACTOR A; MYC PROTEIN; PROTEIN KINASE B; PYRUVATE DEHYDROGENASE KINASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; SUCCINATE DEHYDROGENASE; VIMENTIN; DNA BINDING PROTEIN; MITOCHONDRIAL PROTEIN; TFAM PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ACIDIFICATION; ARTICLE; BASAL METABOLIC RATE; CELL INVASION; CELL METABOLISM; CELL MIGRATION; CONTROLLED STUDY; COPY NUMBER VARIATION; DOWN REGULATION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING; CARCINOMA, RENAL CELL; CELL SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; KIDNEY NEOPLASMS; TUMOR CELL LINE;

CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL SURVIVAL; DNA COPY NUMBER VARIATIONS; DNA, MITOCHONDRIAL; DNA-BINDING PROTEINS; DOXORUBICIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; KIDNEY NEOPLASMS; MITOCHONDRIAL PROTEINS; TRANSCRIPTION FACTORS;

EID: 85015595688     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17060814     Document Type: Article

References (71)

1. Bratic, I.; Trifunovic, A. Mitochondrial energy metabolism and ageing. Biochim. Biophys. Acta 2010, 1797, 961–967. [CrossRef] [PubMed]
2. Lee, H.C.; Wei, Y.H. Mitochondrial role in life and death of the cell. J. Biomed. Sci. 2000, 7, 2–15. [CrossRef] [PubMed]
3. Rafelski, S.M. Mitochondrial network morphology: Building an integrative, geometrical view. BMC Biol. 2013, 11, 71–79. [CrossRef] [PubMed]
4. Busch, K.B.; Kowald, A.; Spelbrink, J.N. Quality matters: How does mitochondrial network dynamics and quality control impact on mtDNA integrity? Philos. Trans. R. Soc. Lond. B Biol. Sci. 2014, 369. [CrossRef] [PubMed]
5. Chan, D.C. Mitochondria: Dynamic organelles in disease, aging, and development. Cell 2006, 125, 1241–1252. [CrossRef] [PubMed]
6. Lee, H.C.; Wei, Y.H. Mitochondrial biogenesis and mitochondrial DNA maintenance of mammalian cells under oxidative stress. Int. J. Biochem. Cell Biol. 2005, 37, 822–834. [CrossRef] [PubMed]
7. Lee, H.C.; Wei, Y.H. Oxidative stress, mitochondrial DNA mutation, and apoptosis in aging. Exp. Biol. Med. 2007, 232, 592–606.
8. Moraes, C.T. What regulates mitochondrial DNA copy number in animal cells? Trends Genet. 2001, 17, 199–205. [CrossRef]
9. Asin-Cayuela, J.; Gustafsson, C.M. Mitochondrial transcription and its regulation in mammalian cells. Trends Biochem. Sci. 2007, 32, 111–117. [CrossRef] [PubMed]
10. Dang, C.V.; Semenza, G.L. Oncogenic alterations of metabolism. Trends Biochem. Sci. 1999, 24, 68–72. [CrossRef]
11. Zeng, W.; Liu, P.; Pan, W.; Singh, S.R.; Wei, Y. Hypoxia and hypoxia inducible factors in tumor metabolism. Cancer Lett. 2015, 356, 263–267. [CrossRef] [PubMed]
12. Warburg, O. On the origin of cancer cells. Science 1956, 123, 309–314. [CrossRef] [PubMed]
13. Kim, J.W.; Dang, C.V. Cancer’s molecular sweet tooth and theWarburg effect. Cancer Res. 2006, 66, 8927–8930. [CrossRef] [PubMed]
14. Warburg, O.; Wind, F.; Negelein, E. The metabolism of tumors in the body. J. Gen. Physiol. 1927, 8, 519–530. [CrossRef] [PubMed]
15. Lee, H.C.; Wei, Y.H. Mitochondrial DNA instability and metabolic shift in human cancers. Int. J. Mol. Sci. 2009, 10, 674–701. [CrossRef] [PubMed]
16. Lin, C.-S.; Wang, L.-S. Mitochondrial DNA instability in human cancers. Formos. J. Surg. 2013, 46, 71–75. [CrossRef]
17. Reznik, E.; Miller, M.L.; Senbabaoglu, Y.; Riaz, N.; Sarungbam, J.; Tickoo, S.K.; Al-Ahmadie, H.A.; Lee, W.; Seshan, V.E.; Hakimi, A.A.; et al. Mitochondrial DNA copy number variation across human cancers. eLife 2016. [CrossRef] [PubMed]
18. Cheau-Feng Lin, F.; Jeng, Y.C.; Huang, T.Y.; Chi, C.S.; Chou, M.C.; Chin-Shaw Tsai, S. Mitochondrial DNA copy number is associated with diagnosis and prognosis of head and neck cancer. Biomarkers 2014, 19, 269–274. [CrossRef] [PubMed]
19. Kim, M.M.; Clinger, J.D.; Masayesva, B.G.; Ha, P.K.; Zahurak, M.L.; Westra, W.H.; Califano, J.A. Mitochondrial DNA quantity increases with histopathologic grade in premalignant and malignant head and neck lesions. Clin. Cancer Res. 2004, 10, 8512–8515. [CrossRef] [PubMed]
20. Lin, C.S.; Chang, S.C.; Wang, L.S.; Chou, T.Y.; Hsu, W.H.; Wu, Y.C.; Wei, Y.H. The role of mitochondrial DNA alterations in esophageal squamous cell carcinomas. J. Thorac. Cardiovasc. Surg. 2010, 139, 189–197. [CrossRef] [PubMed]
21. Lin, C.S.; Wang, L.S.; Chou, T.Y.; Hsu, W.H.; Lin, H.C.; Lee, S.Y.; Lee, M.H.; Chang, S.C.; Wei, Y.H. Cigarette smoking and hOGG1 Ser326Cys polymorphism are associated with 8-OHdG accumulation on mitochondrial DNA in thoracic esophageal squamous cell carcinoma. Ann. Surg. Oncol. 2013, 20 (Suppl. S3), S379–S388. [CrossRef] [PubMed]
22. Lin, C.S.; Wang, L.S.; Chang, S.C.; Chou, T.Y.; Hsu, W.H.; Liu, C.S.; Lee, M.H.; Chung, M.Y.; Wei, Y.H. Associated microsatellite alterations in mitochondrial DNA and in TP53 in thoracic esophageal squamous cell carcinoma. Oncol. Rep. 2012, 28, 69–76. [PubMed]
23. Lee, H.C.; Yin, P.H.; Lin, J.C.; Wu, C.C.; Chen, C.Y.; Wu, C.W.; Chi, C.W.; Tam, T.N.; Wei, Y.H. Mitochondrial genome instability and mtDNA depletion in human cancers. Ann. N. Y. Acad. Sci. 2005, 1042, 109–122. [CrossRef] [PubMed]
24. Tseng, L.M.; Yin, P.H.; Chi, C.W.; Hsu, C.Y.; Wu, C.W.; Lee, L.M.; Wei, Y.H.; Lee, H.C. Mitochondrial DNA mutations and mitochondrial DNA depletion in breast cancer. Genes Chromosomes Cancer 2006, 45, 629–638. [CrossRef] [PubMed]
25. Wu, C.W.; Yin, P.H.; Hung, W.Y.; Li, A.F.; Li, S.H.; Chi, C.W.; Wei, Y.H.; Lee, H.C. Mitochondrial DNA mutations and mitochondrial DNA depletion in gastric cancer. Genes Chromosomes Cancer 2005, 44, 19–28. [CrossRef] [PubMed]
26. Lin, C.S.; Wang, L.S.; Tsai, C.M.; Wei, Y.H. Low copy number and low oxidative damage of mitochondrial DNA are associated with tumor progression in lung cancer tissues after neoadjuvant chemotherapy. Interact. Cardiovasc. Thorac. Surg. 2008, 7, 954–958. [CrossRef] [PubMed]
27. Yin, P.H.; Lee, H.C.; Chau, G.Y.; Wu, Y.T.; Li, S.H.; Lui, W.Y.; Wei, Y.H.; Liu, T.Y.; Chi, C.W. Alteration of the copy number and deletion of mitochondrial DNA in human hepatocellular carcinoma. Br. J. Cancer 2004, 90, 2390–2396. [CrossRef]
28. Tanaka, T.; Nangaku, M. Angiogenesis and hypoxia in the kidney. Nat. Rev. Nephrol. 2013, 9, 211–222. [CrossRef]
29. Simonnet, H.; Alazard, N.; Pfeiffer, K.; Gallou, C.; Beroud, C.; Demont, J.; Bouvier, R.; Schagger, H.; Godinot, C. Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma. Carcinogenesis 2002, 23, 759–768. [CrossRef] [PubMed]
30. Shen, Y.A.; Wang, C.Y.; Hsieh, Y.T.; Chen, Y.J.; Wei, Y.H. Metabolic reprogramming orchestrates cancer stem cell properties in nasopharyngeal carcinoma. Cell Cycle 2015, 14, 86–98. [CrossRef]
31. Mu, W.; Hu, C.; Zhang, H.; Qu, Z.; Cen, J.; Qiu, Z.; Li, C.; Ren, H.; Li, Y.; He, X.; et al. miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res. 2015, 25, 477–495. [CrossRef] [PubMed]
32. Inoue, H.; Hwang, S.H.; Wecksler, A.T.; Hammock, B.D.; Weiss, R.H. Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy. Cancer Biol. Ther. 2011, 12, 827–836. [CrossRef] [PubMed]
33. LaGory, E.L.; Wu, C.; Taniguchi, C.M.; Ding, C.K.; Chi, J.T.; von Eyben, R.; Scott, D.A.; Richardson, A.D.; Giaccia, A.J. Suppression of PGC-1α is critical for reprogramming oxidative metabolism in renal cell carcinoma. Cell Rep. 2015, 12, 116–127. [CrossRef] [PubMed]
34. Lin, C.S.; Lee, H.T.; Lee, S.Y.; Shen, Y.A.; Wang, L.S.; Chen, Y.J.; Wei, Y.H. High mitochondrial DNA copy number and bioenergetic function are associated with tumor invasion of esophageal squamous cell carcinoma cell lines. Int. J. Mol. Sci. 2012, 13, 11228–11246. [CrossRef] [PubMed]
35. Lin, C.S.; Chang, S.C.; Ou, L.H.; Chen, C.M.; Hsieh, S.S.; Chung, Y.P.; King, K.L.; Lin, S.L.; Wei, Y.H. Mitochondrial DNA alterations correlate with the pathological status and the immunological ER, PR, HER-2/neu, p53 and Ki-67 expression in breast invasive ductal carcinoma. Oncol. Rep. 2015, 33, 2924–2934. [CrossRef] [PubMed]
36. Meierhofer, D.; Mayr, J.A.; Foetschl, U.; Berger, A.; Fink, K.; Schmeller, N.; Hacker, G.W.; Hauser-Kronberger, C.; Kofler, B.; Sperl, W. Decrease of mitochondrial DNA content and energy metabolism in renal cell carcinoma. Carcinogenesis 2004, 25, 1005–1010. [CrossRef] [PubMed]
37. Dang, C.V. Links between metabolism and cancer. Genes Dev. 2012, 26, 877–890. [CrossRef] [PubMed]
38. Koppenol, W.H.; Bounds, P.L.; Dang, C.V. Otto Warburg’s contributions to current concepts of cancer metabolism. Nat. Rev. Cancer 2011, 11, 325–337. [CrossRef] [PubMed]
39. Singh, K.K.; Ayyasamy, V.; Owens, K.M.; Koul, M.S.; Vujcic, M. Mutations in mitochondrial DNA polymerase- promote breast tumorigenesis. J. Hum. Genet. 2009, 54, 516–524. [CrossRef] [PubMed]
40. Guo, J.; Zheng, L.; Liu, W.; Wang, X.; Wang, Z.; French, A.J.; Kang, D.; Chen, L.; Thibodeau, S.N. Frequent truncating mutation of TFAM induces mitochondrial DNA depletion and apoptotic resistance in microsatellite-unstable colorectal cancer. Cancer Res. 2011, 71, 2978–2987. [CrossRef] [PubMed]
41. Lincet, H.; Icard, P. How do glycolytic enzymes favour cancer cell proliferation by nonmetabolic functions? Oncogene 2015, 34, 3751–3759. [CrossRef] [PubMed]
42. Kim, J.W.; Dang, C.V. Multifaceted roles of glycolytic enzymes. Trends Biochem. Sci. 2005, 30, 142–150. [CrossRef] [PubMed]
43. Pinthus, J.H.; Whelan, K.F.; Gallino, D.; Lu, J.P.; Rothschild, N. Metabolic features of clear-cell renal cell carcinoma: Mechanisms and clinical implications. Can. Urol. Assoc. J. 2011, 5, 274–282. [CrossRef] [PubMed]
44. Masson, N.; Ratcliffe, P.J. Hypoxia signaling pathways in cancer metabolism: The importance of co-selecting interconnected physiological pathways. Cancer Metab. 2014, 2, 3. [CrossRef] [PubMed]
45. Shinojima, T.; Oya, M.; Takayanagi, A.; Mizuno, R.; Shimizu, N.; Murai, M. Renal cancer cells lacking hypoxia inducible factor (HIF)-1α expression maintain vascular endothelial growth factor expression through HIF-2α. Carcinogenesis 2007, 28, 529–536. [CrossRef] [PubMed]
46. Kim, J.W.; Tchernyshyov, I.; Semenza, G.L.; Dang, C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006, 3, 177–185. [CrossRef] [PubMed]
47. Loboda, A.; Jozkowicz, A.; Dulak, J. HIF-1 and HIF-2 transcription factors-similar but not identical. Mol. Cells 2010, 29, 435–442. [CrossRef] [PubMed]
48. Wang, V.; Davis, D.A.; Haque, M.; Huang, L.E.; Yarchoan, R. Differential gene up-regulation by hypoxia-inducible factor-1α and hypoxia-inducible factor-2_ in HEK293t cells. Cancer Res. 2005, 65, 3299–3306. [PubMed]
49. Lum, J.J.; Bui, T.; Gruber, M.; Gordan, J.D.; DeBerardinis, R.J.; Covello, K.L.; Simon, M.C.; Thompson, C.B. The transcription factor HIF-1α plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev. 2007, 21, 1037–1049. [CrossRef] [PubMed]
50. Franovic, A.; Holterman, C.E.; Payette, J.; Lee, S. Human cancers converge at the HIF-2_ oncogenic axis. Proc. Natl. Acad. Sci. USA 2009, 106, 21306–21311. [CrossRef] [PubMed]
51. Elstrom, R.L.; Bauer, D.E.; Buzzai, M.; Karnauskas, R.; Harris, M.H.; Plas, D.R.; Zhuang, H.; Cinalli, R.M.; Alavi, A.; Rudin, C.M.; et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004, 64, 3892–3899. [CrossRef] [PubMed]
52. Zoncu, R.; Efeyan, A.; Sabatini, D.M. mTOR: From growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 2011, 12, 21–35. [CrossRef] [PubMed]
53. Xu, B.; Gogol, M.; Gaudenz, K.; Gerton, J.L. Improved transcription and translation with L-leucine stimulation of mTORC1 in Roberts syndrome. BMC Genom. 2016, 17. [CrossRef] [PubMed]
54. Xu, B.; Lee, K.K.; Zhang, L.; Gerton, J.L. Stimulation of mtorc1 with L-leucine rescues defects associated with roberts syndrome. PLoS Genet. 2013, 9, e1003857. [CrossRef] [PubMed]
55. Morita, M.; Gravel, S.P.; Hulea, L.; Larsson, O.; Pollak, M.; St-Pierre, J.; Topisirovic, I. mTOR coordinates protein synthesis, mitochondrial activity and proliferation. Cell Cycle 2015, 14, 473–480. [CrossRef] [PubMed]
56. Masui, K.; Tanaka, K.; Akhavan, D.; Babic, I.; Gini, B.; Matsutani, T.; Iwanami, A.; Liu, F.; Villa, G.R.; Gu, Y.; et al. mTOR complex 2 controls glycolytic metabolism in glioblastoma through Foxo acetylation and upregulation of c-MYC. Cell Metab. 2013, 18, 726–739. [CrossRef] [PubMed]
57. Cairns, R.A.; Harris, I.S.; Mak, T.W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 2011, 11, 85–95. [CrossRef] [PubMed]
58. Pedersen, P.L. Warburg, me and hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers’ most common phenotypes, the “Warburg effect”, i.e., elevated glycolysis in the presence of oxygen. J. Bioenerg. Biomembr. 2007, 39, 211–222. [CrossRef] [PubMed]
59. Zhao, Y.; Butler, E.B.; Tan, M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 2013, 4. [CrossRef] [PubMed]
60. Lu, F. Reactive oxygen species in cancer, too much or too little? Med. Hypoth. 2007, 69, 1293–1298. [CrossRef] [PubMed]
61. Qinghong, S.; Shen, G.; Lina, S.; Yueming, Z.; Xiaoou, L.; Jianlin, W.; Chengyan, H.; Hongjun, L.; Haifeng, Z. Comparative proteomics analysis of differential proteins in response to doxorubicin resistance in myelogenous leukemia cell lines. Proteome Sci. 2015, 13, 1–12. [CrossRef] [PubMed]
62. Clevers, H. The cancer stem cell: Premises, promises and challenges. Nat. Med. 2011, 17, 313–319. [CrossRef] [PubMed]
63. Pacini, N.; Borziani, F. Cancer stem cell theory and the Warburg effect, two sides of the same coin? Int. J. Mol. Sci. 2014, 15, 8893–8930. [CrossRef] [PubMed]
64. Menendez, J.A.; Joven, J.; Cufi, S.; Corominas-Faja, B.; Oliveras-Ferraros, C.; Cuyas, E.; Martin-Castillo, B.; Lopez-Bonet, E.; Alarcon, T.; Vazquez-Martin, A. The Warburg effect version 2.0: Metabolic reprogramming of cancer stem cells. Cell Cycle 2013, 12, 1166–1179. [CrossRef] [PubMed]
65. Chen, H.C.; Lee, J.T.; Shih, C.P.; Chao, T.T.; Sytwu, H.K.; Li, S.L.; Fang, M.C.; Chen, H.K.; Lin, Y.C.; Kuo, C.Y.; et al. Hypoxia induces a metabolic shift and enhances the stemness and expansion of cochlear spiral ganglion stem/progenitor cells. BioMed Res. Int. 2015. [CrossRef] [PubMed]
66. Guha, M.; Srinivasan, S.; Ruthel, G.; Kashina, A.K.; Carstens, R.P.; Mendoza, A.; Khanna, C.; van Winkle, T.; Avadhani, N.G. Mitochondrial retrograde signaling induces epithelial-mesenchymal transition and generates breast cancer stem cells. Oncogene 2014, 33, 5238–5250. [CrossRef] [PubMed]
67. Lee, H.T.; Lin, C.S.; Chen, W.S.; Liao, H.T.; Tsai, C.Y.; Wei, Y.H. Leukocyte mitochondrial DNA alteration in systemic lupus erythematosus and its relevance to the susceptibility to lupus nephritis. Int. J. Mol. Sci. 2012, 13, 8853–8868. [CrossRef] [PubMed]
68. Lee, H.T.; Lin, C.S.; Lee, C.S.; Tsai, C.Y.; Wei, Y.H. Increased 8-hydroxy-21-deoxyguanosine in plasma and decreased mrna expression of human 8-oxoguanine DNA glycosylase 1, antioxidant enzymes, mitochondrial biogenesis-related proteins and glycolytic enzymes in leucocytes in patients with systemic lupus erythematosus. Clin. Exp. Immunol. 2014, 176, 66–77.
69. Dang, C.V. The interplay between myc and HIF in the Warburg effect. Ernst Scher. Found. Symp. Proc. 2007. [CrossRef]
70. Robey, R.B.; Hay, N. Is Akt the “Warburg kinase”?—Akt-Energy metabolism interactions and oncogenesis. Semin. Cancer Biol. 2009, 19, 25–31. [CrossRef] [PubMed]
71. Schulz, N.; Kluth, O.; Jastroch, M.; Schurmann, A. Minor role of mitochondrial respiration for fatty-acid induced insulin secretion. Int. J. Mol. Sci. 2013, 14, 18989–18998. [CrossRef] [PubMed]